JP2022535064A - 肺炎レンサ球菌血清型２９から保護する免疫原性組成物で患者を治療する方法 - Google Patents

肺炎レンサ球菌血清型２９から保護する免疫原性組成物で患者を治療する方法 Download PDF

Info

Publication number
JP2022535064A
JP2022535064A JP2021571699A JP2021571699A JP2022535064A JP 2022535064 A JP2022535064 A JP 2022535064A JP 2021571699 A JP2021571699 A JP 2021571699A JP 2021571699 A JP2021571699 A JP 2021571699A JP 2022535064 A JP2022535064 A JP 2022535064A
Authority
JP
Japan
Prior art keywords
polysaccharide
protein
serotype
protein conjugate
serotypes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021571699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535064A5 (https=
JPWO2020247301A5 (https=
Inventor
ヘ，ジアン
カウフホールド，ロビン・エム
スキナー，ジュリー・エム
シエ，ジンフー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2022535064A publication Critical patent/JP2022535064A/ja
Publication of JP2022535064A5 publication Critical patent/JP2022535064A5/ja
Publication of JPWO2020247301A5 publication Critical patent/JPWO2020247301A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2021571699A 2019-06-05 2020-06-01 肺炎レンサ球菌血清型２９から保護する免疫原性組成物で患者を治療する方法 Pending JP2022535064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857534P 2019-06-05 2019-06-05
US62/857,534 2019-06-05
PCT/US2020/035511 WO2020247301A1 (en) 2019-06-05 2020-06-01 Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29

Publications (3)

Publication Number Publication Date
JP2022535064A true JP2022535064A (ja) 2022-08-04
JP2022535064A5 JP2022535064A5 (https=) 2023-06-20
JPWO2020247301A5 JPWO2020247301A5 (https=) 2023-06-20

Family

ID=73653320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571699A Pending JP2022535064A (ja) 2019-06-05 2020-06-01 肺炎レンサ球菌血清型２９から保護する免疫原性組成物で患者を治療する方法

Country Status (10)

Country Link
US (1) US20220218812A1 (https=)
EP (1) EP3980050A4 (https=)
JP (1) JP2022535064A (https=)
KR (1) KR20220016964A (https=)
CN (1) CN114025784A (https=)
AU (1) AU2020289048A1 (https=)
BR (1) BR112021024491A8 (https=)
CA (1) CA3142697A1 (https=)
MX (1) MX2021014948A (https=)
WO (1) WO2020247301A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
WO2019050813A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064444A1 (en) * 2016-09-30 2018-04-05 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311976A1 (en) * 2009-10-19 2011-04-20 Azienda Ospedaliero-Universitaria Meyer Method for Streptococcus Pneumoniae diagnosis and serotyping
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
EP4488286A3 (en) * 2016-03-31 2025-04-02 Pogona, Llc Saccharide-polypeptide conjugate compositions and methods of use thereof
ES3024474T3 (en) * 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064444A1 (en) * 2016-09-30 2018-04-05 Biological E Limited Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. INFECT. DIS., vol. 211, no. 7, JPN6024018336, 2015, pages 1144 - 1153, ISSN: 0005630408 *
JOURNAL OF CLINICAL MICROBIOLOGY, vol. Vol.55, Issue5, JPN6024018337, 2017, pages 1416 - 1425, ISSN: 0005630409 *
VACCINE, vol. 29, no. 41, JPN6024018338, 2011, pages 7207 - 7211, ISSN: 0005480303 *

Also Published As

Publication number Publication date
CA3142697A1 (en) 2020-12-10
BR112021024491A2 (pt) 2022-02-15
MX2021014948A (es) 2022-01-24
WO2020247301A1 (en) 2020-12-10
EP3980050A4 (en) 2023-08-02
BR112021024491A8 (pt) 2023-04-11
CN114025784A (zh) 2022-02-08
KR20220016964A (ko) 2022-02-10
EP3980050A1 (en) 2022-04-13
US20220218812A1 (en) 2022-07-14
AU2020289048A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US20240342263A1 (en) Methods for making polysaccharide-protein conjugates
KR102686858B1 (ko) 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
US11883502B2 (en) Methods for production of capsular polysaccharide protein conjugates from Streptococcus pneumoniae serotype 19F
US20240382576A1 (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
KR101538535B1 (ko) 15가 폐렴구균성 폴리사카라이드-단백질 접합체 백신 조성물
JP2022535064A (ja) 肺炎レンサ球菌血清型２９から保護する免疫原性組成物で患者を治療する方法
JP2022535063A (ja) 免疫原性血清型３５ｂ肺炎球菌多糖類－タンパク質コンジュゲート及びそれを作成するためのコンジュゲーションプロセス
KR20240011879A (ko) 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250701